Fig. 1From: Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical settingPatient disposition flow diagram. Treated set included 64 noneligible patients. Eligibility to participate and reasons for discontinuation were noted by investigators by completion of tick boxes. SmPC Summary of Product CharacteristicsBack to article page